Moderna Launches New Manufacturing and R&D Facility in the UK

Moderna, Inc. has officially opened its Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire. This new facility will produce British-made mRNA vaccines for the UK's NHS seasonal vaccination programs. Additionally, the center will research mRNA applications for cancer, rare diseases, and immune disorders.

The MITC is a key part of Moderna's ten-year strategic partnership with the UK Government, aimed at enhancing health resilience and boosting economic growth. It is the first UK facility to produce mRNA vaccines locally, underscoring the UK's commitment to health security.

The MITC can manufacture up to 100 million mRNA vaccine doses annually, expandable to 250 million during pandemics. It joins a global network of Moderna facilities enhancing pandemic readiness.